QS Investors LLC grew its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 3.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 65,484 shares of the medical research company’s stock after buying an additional 2,376 shares during the period. QS Investors LLC owned 0.10% of PRA Health Sciences worth $5,964,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. IFP Advisors Inc raised its holdings in shares of PRA Health Sciences by 19,083.3% in the fourth quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock valued at $105,000 after buying an additional 1,145 shares during the last quarter. Intrust Bank NA purchased a new position in PRA Health Sciences during the fourth quarter worth about $204,000. Comerica Bank purchased a new position in PRA Health Sciences during the third quarter worth about $214,000. Parametrica Management Ltd purchased a new position in PRA Health Sciences during the fourth quarter worth about $232,000. Finally, ETRADE Capital Management LLC purchased a new position in PRA Health Sciences during the fourth quarter worth about $246,000. 99.28% of the stock is owned by institutional investors and hedge funds.
In other PRA Health Sciences news, EVP David W. Dockhorn sold 72,850 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. Following the completion of the transaction, the executive vice president now directly owns 72,850 shares of the company’s stock, valued at $6,616,965.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Linda Baddour sold 67,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total transaction of $6,048,090.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 212,700 shares of company stock valued at $19,282,021. 2.10% of the stock is currently owned by corporate insiders.
PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.02. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The company had revenue of $568.80 million during the quarter, compared to analysts’ expectations of $543.78 million. During the same period last year, the company posted $0.71 earnings per share. The firm’s quarterly revenue was up 37.5% compared to the same quarter last year. equities research analysts anticipate that PRA Health Sciences Inc will post 3.81 EPS for the current year.
Several research firms recently issued reports on PRAH. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 price target for the company in a report on Thursday, January 11th. Credit Suisse Group reissued an “outperform” rating and set a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a report on Thursday, February 22nd. Robert W. Baird set a $94.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $95.67.
COPYRIGHT VIOLATION WARNING: “QS Investors LLC Increases Stake in PRA Health Sciences Inc (PRAH)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/qs-investors-llc-increases-stake-in-pra-health-sciences-inc-prah.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.